Product Information

PIOGLITAZONE-GLIMEPIRIDE 30-2 is a generic product labeled by Prasco Laboratories, priced at $10.7597 per EA under NDC 66993082130. Its NADAC has been published 185 times since Oct 7, 2015.

FDA first approved this application on Jul 28, 2006. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

PIOGLITAZONE-GLIMEPIRIDE 30-2

pioglitazone and glimepiride
$10.7597per EA

Strength

2; 30 mg/1; mg/1

NDC

66993082130

Classification

Generic

Dosage Form

TABLET

Route

ORAL

Effective Date

8/19/2026

Approval Type

Authorized Generic (NDA)

FDA Application

NDA021925

FDA Approved

7/28/2006

TE Code

AB

On Market Since

8/4/2015

Pharmacological Classes

Peroxisome Proliferator Receptor alpha Agonist
Peroxisome Proliferator Receptor gamma Agonist
Peroxisome Proliferator-activated Receptor alpha Agonists
Peroxisome Proliferator-activated Receptor gamma Agonists
Sulfonylurea Compounds
Sulfonylurea
Thiazolidinedione
Thiazolidinediones

Price Statistics

The NADAC for PIOGLITAZONE-GLIMEPIRIDE 30-2 has been published 185 times since Oct 7, 2015, and over the history we have for it it has risen 18.3%. The table below summarizes its recorded NADAC range and movement.

Current price$10.7597 per EA
All-time high$11.3091 (Jan 10, 2018)
All-time low$7.2022 (Aug 21, 2024)
52-week high$10.8009
52-week low$10.5207
Median price$10.5207
Average price$10.0801
Largest weekly change-36.3% (Aug 21, 2024)
Weeks tracked185
Tracking sinceOct 7, 2015

Price History

1W

0.0%

1M

0.0%

3M

-0.4%

6M

-0.4%

1Y

+2.3%

3Y

-4.9%

5Y

-4.9%

All

+18.3%

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Frequently asked questions

What is the NADAC price of PIOGLITAZONE-GLIMEPIRIDE 30-2?

The current National Average Drug Acquisition Cost (NADAC) for PIOGLITAZONE-GLIMEPIRIDE 30-2, manufactured by Prasco Laboratories, is $10.7597 per EA (NDC 66993082130), effective Aug 19, 2026.

How has the price of PIOGLITAZONE-GLIMEPIRIDE 30-2 changed over time?

Over the history we have for it, the NADAC for PIOGLITAZONE-GLIMEPIRIDE 30-2 has risen 18.3%. It has been tracked across 185 weekly CMS publications since Oct 7, 2015.

What are the highest and lowest recorded NADAC prices for PIOGLITAZONE-GLIMEPIRIDE 30-2?

Since Oct 7, 2015, the NADAC for PIOGLITAZONE-GLIMEPIRIDE 30-2 has ranged from a low of $7.2022 (Aug 21, 2024) to a high of $11.3091 (Jan 10, 2018), with a median of $10.5207 per EA.

Are there cheaper alternatives to PIOGLITAZONE-GLIMEPIRIDE 30-2?

1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as PIOGLITAZONE-GLIMEPIRIDE 30-2 in a comparable dosage form, but none are currently priced below it.

Who manufactures PIOGLITAZONE-GLIMEPIRIDE 30-2?

PIOGLITAZONE-GLIMEPIRIDE 30-2 (NDC 66993082130) is labeled by Prasco Laboratories, and CMS classifies it as a generic product.